DBV Technologies, a French biopharmaceutical company, has welcomed Lucia Septién as Chief Medical Officer. She will provide strategic input and oversight into the company’s clinical development programmes and medical affairs.
Working with Hugh Sampson and Laurent Martin, DBV’s Chief Scientific Officer and Chief Development Officer, respectively, Septién will be instrumental in the advancement of the company’s lead product candidate, Viaskin Peanut, through its Phase III trial to appropriate regulatory submissions.
Septién will also have a key role in accelerating the development of other Viaskin product candidates in and beyond food allergies.
Septién has more than 20 years of experience in the pharmaceutical industry, where she has a strong track record in drug development and medical affairs. She has held several senior positions, leading R&D and Portfolio Management Strategy teams in a wide range of therapeutic areas, including small molecules and biologicals. She spent most of her career at Pfizer and Wyeth. At Pfizer, she served as Vice President of the Speciality Care Business Unit, Europe.
Prior to Pfizer, Septién worked at Wyeth Pharma as Assistant Vice President, Global Neuroscience, responsible for major Phase II and III development programs, including the clinical studies of monoclonal antibodies in Alzheimer's disease in more than 27 countries.
Before joining DBV, Septién was Vice President, Global Neurosciences, responsible for the Medical Strategy of the Botulinum Toxin portfolio at Ipsen. She earned her medical degree and specialised in Psychiatry at the National University of Mexico City. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l'Energie Atomique in Saclay, France.
